Current maintenance or controller treatments for COPD include tiotropoium, LAMA, LABA, LABA + ICS, LAMA + LABA, roflumilast, theophylline, and 'triple therapy' combining LAMA + LABA + ICS.

Nearly 50% of patients were initially prescribed LABA/inhaled corticosteroids. BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016, 32,558 patients ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

The near-term pipeline for COPD has several ICS, LABA and LAMA combinations in development with claims of improved efficacy and better safety profiles. Moreover, the development of more innovative ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

is more effective than a LABA combined with an inhaled corticosteroid (ICS) in moderate-to-severe COPD. In the study Spiolto - which combines tiotropium, the active ingredient in Boehringer's LAMA ...

In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA) experienced superior improvements in lung ...

Black Americans have a higher likelihood of having asthma-COPD overlap syndrome (ACOS) but may not know it. Here’s what you ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

The Spanish COPD guidelines recommend treatment of the ... to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more severe cases, theophylline or roflumilast may ...